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1 
Serum TSH in thyroid cancer: does it matter? 21 
Abstract 22 
Differentiated thyroid cancer is the most common endocrine malignancy and the incidence is 23 
increasing rapidly worldwide. Appropriate diagnosis and post-treatment monitoring of patients with 24 
thyroid tumours is critical. Fine needle aspiration cytology remains the gold standard for diagnosing 25 
thyroid cancer and whilst there have been significant refinements to this technique, diagnostic 26 
surgery is often required for patients suspected to have malignancy. Serum thyroid stimulating 27 
hormone (TSH) is higher in patients with malignant thyroid nodules compared to those with benign 28 
disease, and TSH is proportionally increased in more aggressive tumours. Importantly, we have 29 
shown that the pre-operative serum TSH concentration independently predicts the presence of 30 
malignancy in subjects presenting with thyroid nodules. Establishing the use of TSH measurements 31 
in algorithms identifying high risk thyroid nodules in routine clinical practice represents an exciting, 32 
cost-efficient and non-invasive approach to optimise thyroid cancer diagnosis. Binding of TSH to 33 
receptors on thyrocytes stimulates a number of growth promoting pathways both in normal and 34 
malignant thyroid cells and TSH suppression with high doses of levothyroxine is routinely used 35 
following thyroidectomy in order to prevent cancer recurrence, especially in high risk tumours. This 36 
review examines the relationship between serum TSH and thyroid cancer and reflects on the clinical 37 
potential of TSH measurements in diagnosis and disease monitoring.   38 
  39 
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TSH in thyroid cancer: does it matter? 40 
Introduction  41 
Differentiated thyroid malignancy is the most common endocrine malignancy and over the 42 
last few decades, its incidence has increased dramatically worldwide (Kitahara and Sosa 2016; Sipos 43 
and Mazzaferri 2010). It is currently the fifth most common malignancy in women in the US and an 44 
estimated 62,000 new cases were found in North American men and women in 2015 (American 45 
Cancer Society 2015). Thyroid cancer causes more deaths than any other endocrine cancer (Monson 46 
2000) and there will be an estimated 1,980 deaths from thyroid cancer in the US in 2016 (American 47 
Cancer Society 2016). The reasons for the observed increase in incidence have been widely debated 48 
(Wartofsky 2010) and include enhanced detection of subclinical thyroid cancer due to the growing 49 
use of diagnostic imaging as well as exposure to a number of environmental factors (Kitahara and 50 
Sosa 2016). Whilst better access to health care in countries with high socio-economic status may in 51 
part explain the rising incidence, observations of increased thyroid cancer rates in lower socio-52 
economic countries, an increasing number of larger tumours as well as the changing thyroid cancer 53 
molecular profiles indicate that other factors are likely to be involved (Vigneri, et al. 2015). A 54 
number of disease modifiable factors including obesity have been identified as potential aetiological 55 
factors (Schmid, et al. 2015). Moreover a variety of thyroid-specific environmental carcinogens have 56 
been implicated including ionising radiation, increased dietary iodine intake and environmental 57 
pollutants (Vigneri et al. 2015). Overall, the observed changes in thyroid cancer incidence are likely 58 
due to a combination of detection bias and true increases in incidence. 59 
Thyroid cancer often presents as a solitary nodule or as a part of a multinodular goitre. This 60 
creates an important clinical dilemma as thyroid nodules are very common occurring in 50-67% of 61 
the population and more than 90% are benign (Durante, et al. 2015; Hegedus 2004; Mazzaferri 1992; 62 
Popoveniuc and Jonklaas 2012). Detection rates of thyroid nodules are increasing due to widespread 63 
use of imaging modalities in advanced health care systems (Cramer, et al. 2010; Popoveniuc and 64 
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Jonklaas 2012). While incidental thyroid neoplasms have long been recognised due to their presence 65 
during post-mortem examinations (Dean and Gharib 2008), there is a significant and increasing 66 
clinical burden associated with detecting this disease in patients (Brito, et al. 2014), for whom the 67 
differentiation between aggressive and indolent diagnoses is crucial (Cabanillas, et al. 2016a). 68 
There are  a number of well-established and evolving clinical tools to discern malignant from 69 
benign thyroid nodules (He, et al. 2016). Most international guidelines recommend the use of a 70 
combination of diagnostic tools, including measurement of thyroid stimulating hormone (TSH) to 71 
assess functional thyroid status, high resolution ultrasonography (US) scanning to assess the 72 
morphological characteristics of the thyroid and nodule(s), and fine needle aspiration biopsy for 73 
cytological evaluation of the presence of malignancy (Hegedus, et al. 2003; Perros, et al. 2014; Pitoia 74 
and Miyauchi 2015). In recent years the use of panels of molecular markers to refine the cytological 75 
diagnosis of malignancy has received significant attention, although these tests are very expensive 76 
and not used routinely in all centres (Xing, et al. 2013). Since most benign nodules do not require 77 
further intervention it is pertinent that thyroid malignancy is diagnosed accurately and further 78 
refinement of current diagnostic approaches is required. 79 
If malignancy is diagnosed, surgery is the primary treatment modality for differentiated 80 
thyroid cancer, followed by adjuvant radioiodine ablative therapy in a significant number of patients 81 
(Burns and Zeiger 2010; Perros et al. 2014; Pitoia and Miyauchi 2015). Since TSH is a growth factor 82 
for thyroid cells, therapy with suppressive doses of levothyroxine is often used postoperatively and 83 
this has long been known to positively affect outcomes in differentiated thyroid cancer (Mazzaferri 84 
and Jhiang 1994; McLeod, et al. 2012; Pujol, et al. 1996). Current guidelines recommend the medium 85 
to long term use of TSH suppression in high risk thyroid cancer but not in lower risk tumours because 86 
of the health risks associated with the induction of subclinical and overt thyrotoxicosis (Perros et al. 87 
2014; Pitoia and Miyauchi 2015). 88 
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The diagnosis and post-therapy monitoring of patients with thyroid nodules and cancer is 89 
important. We were the first to publish that serum TSH is raised in patients with malignant thyroid 90 
nodules compared to those with benign disease (Boelaert et al 2006), and subsequent studies have 91 
shown that pre-operative serum TSH is proportionally higher in those with more aggressive disease 92 
(Boelaert, et al. 2006; Fighera, et al. 2015; Haymart, et al. 2009; Jonklaas, et al. 2008; McLeod, et al. 93 
2014). This review aims to explore the relationship between TSH and thyroid cancer, both before 94 
and after a diagnosis of malignancy is made. 95 
  96 
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Thyroid-stimulating hormone  97 
Hormone structure and biochemical details 98 
Thyroid stimulating hormone (TSH) is a two subunit glycoprotein, released from the pituitary 99 
gland in response to hypothalamic release of thyrotropin releasing hormone (TRH). The alpha 100 
subunit of the glycoprotein is similar to that of luteinising hormone (LH) and follicle-stimulating 101 
hormone (FSH), with specificity only related to the beta subunit. TSH, or thyrotropin, stimulates the 102 
thyroid to produce and secrete thyroxine (T4) and triiodothyronine (T3). The released T4 becomes 103 
effective once converted peripherally to triiodothyronine (T3) by deiodinase enzymes. The 104 
functionally active circulating hormones provide a feedback loop directly to both the hypothalamus 105 
and the pituitary suppressing further release of TSH and TRH, thereby maintaining homeostatic 106 
control of  the hypothalamic-pituitary-thyroid  axis (Magner 1989; Sarapura, et al. 2011; Szkudlinski, 107 
et al. 2002). 108 
TSH function in the normal thyroid  109 
TSH acts on thyroid cells signalling through the TSH receptor, which is found predominantly 110 
on follicular thyroid cells. TSH is a growth factor for thyrocytes, with prolonged exposure causing 111 
hyperplasia and hypertrophy (Sarapura et al. 2011). Stimulation of the TSH receptor causes 112 
activation of the adenylate cyclase pathway, resulting in alterations in cell-cycle proteins causing 113 
changes in thyroid gland growth and cell morphology, as well as the production of thyroid 114 
hormones. The effects of TSH can be broadly summarised as follows: synthesis of thyroid hormones, 115 
thyroid gland growth, changes in thyrocyte morphology, regulation of post-transcriptional activation 116 
of the sodium iodide symporter (NIS) and modulating extra-thyroidal effects (Sarapura et al. 2011).  117 
Diagnosing thyroid malignancy  118 
Types of thyroid cancer 119 
Thyroid cancers arise from thyroid follicular cells or parafollicular cells. Differentiated 120 
thyroid cancer (DTC) includes two subtypes, papillary and follicular cancers, both of which arise from 121 
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follicular cells and together make up 90% of thyroid cancers. Papillary thyroid cancers are the most 122 
common and represent 85% of all thyroid malignancies. Medullary thyroid cancers account for 3-4% 123 
of all thyroid cancers and 80% arise from sporadic mutations, whereas the remainder are hereditary, 124 
usually as part of multiple endocrine neoplasia syndromes. Finally, thyroid cancers can be 125 
undifferentiated, referred to as anaplastic thyroid cancers, and these tumours have the most 126 
aggressive phenotype and the worst prognosis with median survival rates of 3-7 months (Cabanillas, 127 
et al. 2016b).   128 
Current diagnostic approaches and limitations 129 
Guidelines recommend that patients suspected to have thyroid malignancy are assessed by 130 
a physician with a specialist interest in thyroid cancer care, and who is a regular member of the 131 
multi-disciplinary team (Perros et al. 2014). It is paramount to perform a full clinical assessment 132 
which includes taking a personal and family history as well as careful clinical examination (Hegedus 133 
2004; Hegedus et al. 2003; Perros et al. 2014; Pitoia and Miyauchi 2015). In many cases, however, 134 
thyroid glands harboring malignancy are clinically indistinguishable from those that do not and there 135 
is substantial variation among practitioners in evaluating nodules. Features suggestive of malignancy 136 
include the presence of firm, fixed thyroid lumps, vocal cord palsy, a positive family history, rapid 137 
nodule growth and being at the extremities of age (>60 years or <20 years) (Hegedus et al. 2003). 138 
Table 1 displays clinical characteristics associated with an increased risk of malignancy. 139 
 The serum TSH concentration is routinely measured to exclude the presence of a toxic 140 
nodule causing subclinical or overt hyperthyroidism in all patients (Hegedus et al. 2003; Perros et al. 141 
2014; Pitoia and Miyauchi 2015). If the TSH is below the laboratory reference range, assays for free 142 
triiodothyronine (fT3) and free thyroxine (fT4) are required in order to exclude overt 143 
hyperthyroidism (raised free T4 and free T3) or “T3-toxicosis” (raised serum free T3 alone). Similarly, 144 
if TSH is raised then overt hypothyroidism must be excluded (this being indicated by low fT4 with a 145 
raised TSH concentration). Although virtually all patients with thyroid carcinoma are euthyroid, the 146 
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presence of a suppressed serum thyrotrophin (TSH) level (generally indicative of subclinical or overt 147 
thyrotoxicosis) does not rule out the presence of malignancy (Hegedus 2004; Hegedus et al. 2003; 148 
Perros et al. 2014; Pitoia and Miyauchi 2015). Measurement of serum thyroglobulin is of little value 149 
in the initial diagnosis of thyroid cancer whereas this remains an important tumor marker in the 150 
follow-up of patients with thyroid cancer (Perros et al. 2014; Pitoia and Miyauchi 2015). 151 
Measurements of basal plasma calcitonin and carcino-embryonic antigen (CEA) are useful if 152 
medullary carcinoma is suspected but do not form part of the routine evaluation of thyroid nodules 153 
(Perros et al. 2014). 154 
  Thyroid ultrasonography is an extremely sensitive tool for the diagnosis of thyroid nodules 155 
and may be specific in diagnosing papillary thyroid cancer (Cesur, et al. 2006; Hambly, et al. 2011). 156 
Moreover this imaging modality aids the decision-making processes of which nodules to target for 157 
fine needle aspiration biopsy (FNAB) and increases the diagnostic yield of thyroid cell sampling 158 
(American Cancer Society 2015; Perros et al. 2014; Pitoia and Miyauchi 2015). Multiple studies have 159 
confirmed typical sonographic features associated with increased risks of malignancy (Table 160 
2(Frates, et al. 2005; Hambly et al. 2011; Lee, et al. 2011)) and current guidelines now recommend 161 
the use of a combination of these features in algorithms predicting the likelihood of thyroid 162 
malignancy as well as the selection of nodules requiring (FNAB) (Haugen, et al. 2015; Perros et al. 163 
2014; Pitoia and Miyauchi 2015). High resolution ultrasonography by an experienced operator is 164 
highly recommended in the initial evaluation of patients with thyroid nodules. 165 
 Fine needle aspiration cytology remains the gold standard to confirm absence or presence of 166 
thyroid malignancy. The results can confirm that a nodule is benign, triage patients requiring 167 
diagnostic surgery or confirm a diagnosis of malignancy enabling one step therapeutic surgery 168 
(Perros et al. 2014; Pitoia and Miyauchi 2015). In the UK, cytology results are reported using the THY 169 
classification (The Royal College of Pathologists 2009) whereas in the US the Bethesda scoring 170 
system (Bongiovanni, et al. 2012) is employed. Despite accuracy of diagnosis in the majority of 171 
thyroid nodules, FNAC has drawbacks including the sometimes high rate of insufficient/inadequate 172 
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samples, the inability to distinguish between benign and malignant follicular lesions and difficulties 173 
in detecting follicular variant papillary carcinomas (Rago, et al. 2007; Sangalli, et al. 2006).  174 
 Indeterminate or suspicious thyroid lesions represent 10-26% of nodules evaluated 175 
cytologically. These nodules usually require diagnostic surgery and a median 34% of patients with 176 
indeterminate nodules have thyroid malignancy (Xing et al. 2013). In order to avoid unnecessary 177 
thyroidectomy, a number of centres use gene expression classifiers or mutation analysis panels to 178 
further refine the cytological diagnosis. These diagnostic tools however are very expensive and only 179 
routinely available in a limited number of centers world-wide (Bernet, et al. 2014; Pitoia and 180 
Miyauchi 2015). Whilst there have been significant advances in our current diagnostic approaches 181 
for thyroid cancer, further cost-efficient and easily applicable approaches are needed to allow 182 
informed decision making for both physicians and patients when evaluating the likelihood of 183 
malignancy in thyroid nodules. 184 
Serum TSH in the diagnosis of thyroid cancer 185 
TSH and promotion of thyroid cancer growth 186 
Several studies including two large meta-analyses (McLeod et al. 2012; Zheng, et al. 2016) 187 
have confirmed that higher serum TSH is associated with an increased risk of differentiated thyroid 188 
cancer. Table 3 demonstrates a range of original research studies investigating the link between 189 
serum TSH concentrations and differentiated thyroid cancer. Importantly, several studies have 190 
shown higher TSH to predict thyroid malignancy,  independent of other risk factors including 191 
patients’ age and gender as well as a positive family history (Kim, et al. 2013; McLeod et al. 2012). 192 
The first study was performed by our group, and demonstrated an increase in risk of diagnosis of 193 
malignancy in parallel with an increase in serum TSH (Boelaert et al. 2006). The lowest risk of thyroid 194 
cancer diagnosis was in those with a TSH below the lower limit of the reference range (<0.4 mIU/l). 195 
There was a significant cut off at serum TSH of 0.9mIU/l, with an increased risk of cancer diagnosis in 196 
those with serum TSH concentrations above this. The highest risk of cancer diagnosis was in the 197 
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group with subclinical hypothyroidism who had serum TSH >5.5. mIU/l. Importantly we found that, 198 
even within the normal range, higher TSH concentrations correlate with a higher risk of DTC and this 199 
was subsequently confirmed by others (Haymart, et al. 2008).  200 
Higher pre-operative serum TSH concentrations have also been associated with more 201 
advanced cancer stage at diagnosis. Mean serum TSH levels were higher in those with stage III and 202 
IV disease and in those with larger tumours or in cancers associated with lymph node metastases 203 
(Fiore, et al. 2009; Haymart et al. 2008; Shi, et al. 2016). A meta-analysis of 28 studies, analysing 204 
42,032 control subjects and 5,786 patients with thyroid cancers has confirmed that higher pre-205 
operative TSH levels are associated with increased risk of thyroid malignancy as well as a correlation 206 
with higher disease grade (McLeod et al. 2012). A more recent meta-analysis of 56 studies 207 
encompassing 20,227 thyroid cancer cases and 50,003 controls with benign thyroid nodules has 208 
confirmed that higher serum TSH level were significantly associated with thyroid cancer size and 209 
with the presence of lymph node metastasis (Zheng et al. 2016). These findings are consistent with 210 
serum TSH having a role in the promotion of thyroid tumour growth and agressiveness.  211 
Indeed TSH is a known growth factor for thyroid nodules and suppression of serum TSH 212 
concentrations by administering exogenous thyroid hormone may inhibit the growth of established 213 
nodules as well as the development of new nodules (Papini, et al. 1998). Benign and malignant 214 
thyroid tumours express functional TSH receptors on the plasma membrane (Ichikawa, et al. 1976) 215 
and TSH increases adenylate cyclase activity leading to cAMP production and cell growth through 216 
stimulation of these receptors in vitro (Carayon, et al. 1980). Importantly the expression of TSH 217 
receptors in DTC has been associated with an improved prognosis (Shi, et al. 1993). Differentiated 218 
thyroid cancers usually retain responsiveness to TSH and suppressive doses of levothyroxine can be 219 
used to inhibit the progression of metastatic thyroid cancer (Simpson, et al. 1988) as well as 220 
decrease rates of recurrence in patients treated with surgery or radioactive iodine (Biondi, et al. 221 
2005; McGriff, et al. 2002), in keeping with TSH’s tropic effect on thyroid tissue promoting neoplasia 222 
and carcinogenesis. 223 
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TSH and the initiation of thyroid cancer 224 
It has been demonstrated that even in patients who do not present with thyroid nodules, 225 
higher serum TSH concentrations are associated with increased risks of thyroid malignancy. In a 226 
large sample drawn from the general population TSH levels were significantly higher in patients with 227 
DTC when compared with the control group. Among 1,548 controls, 606 subjects had thyroid 228 
nodules detected on ultrasound. Further subgroup analysis demonstrated that control subjects 229 
without detectable thyroid nodules had proportionally higher risks of DTC as TSH concentration 230 
rose, suggesting a role for TSH in the generation of thyroid cancer. This study did not indicate a 231 
relationship between higher serum TSH concentrations and more advanced thyroid cancer in 232 
contrast with others (Fiore et al. 2009; Haymart et al. 2008; McLeod et al. 2012; Zheng et al. 2016). 233 
Evidence for a role of TSH in the development of thyroid tumours comes from studies of the 234 
TRβPV/PV mouse which has a dominant negative mutant thyroid hormone nuclear receptor gene 235 
inserted in the TRβ locus. This mouse model has disrupted pituitary-thyroid axis signalling resulting 236 
in raised serum TSH concentrations and the rapid development of metastatic thyroid cancer (Suzuki, 237 
et al. 2002). Crossing of this model with TSH receptor gene knockout mice (TSHR-/-) resulted in 238 
impaired thyroid growth and no occurrences of thyroid cancer, consistent with a role for TSH in 239 
thyroid tumourigenesis (Lu, et al. 2010). 240 
Serum TSH and thyroid autoimmunity 241 
Several studies have indicated an association between thyroid autoimmunity and thyroid 242 
malignancy (Boelaert 2009; Haymart et al. 2008; McLeod et al. 2012). There is an increased 243 
incidence of thyroid cancer in patients with Hashimoto’s disease. Our previous study (Boelaert et al. 244 
2006) demonstrated that although raised thyroid peroxidase (TPO) levels did not independently 245 
predict malignancy, patients with cancer had significantly higher levels of TPO antibody than 246 
patients with benign disease. Fiore et al. (Fiore et al. 2009) demonstrated that TSH was higher in 247 
patients independent of whether they had raised TPO antibodies or not, and that there was no 248 
difference in rates of thyroid carcinoma between the autoimmune thyroid disease population and 249 
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antibody negative patients. Haymart et al. (Haymart et al. 2008) observed the debate about 250 
association of thyroid cancer with both Hashimoto’s disease and Graves’ disease. They suggest that 251 
as Hashimoto’s disease often progresses to hypothyroidism resulting in elevated TSH 252 
concentrations, and because Graves’ disease is associated with TSH receptor stimulation, which is 253 
associated with thyroid cancer (Mazzaferri 2000), it follows that TSH receptor activation is the link 254 
between thyroid cancer and thyroid autoimmune disease. More recently, a study directed at 255 
assessment of anti-thyroglobulin antibody (TgAb) measured pre-operative levels in differentiated 256 
thyroid cancer patients and concluded that TgAb was not an independent predictor of DTC 257 
prognosis, once adjusted for age and gender (McLeod et al. 2014); they noted that TgAb may be 258 
raised in autoimmunity and in patients exhibiting an immune response to the tumour, and may not 259 
be a true representation of thyroid autoimmune disease. Figure 1 summarises the potential effects 260 
of TSH as a tumour initiator, cancer promoter or in relation to thyroid auto-immunity. 261 
Aetiology of raised serum TSH concentrations in thyroid cancer 262 
There is no consensus on why serum TSH is raised in differentiated thyroid cancer nor do we 263 
fully understand the cause and effect relationship (Boelaert 2009). Iodine deficiency causes a 264 
consequent rise in serum TSH concentrations and chronic iodine deficiency is a well-established risk 265 
factor for the development of goitre and follicular thyroid cancer (Feldt-Rasmussen 2001; Lind, et al. 266 
1998; Nagataki and Nystrom 2002). However, a causal role for TSH in the initiation of thyroid cancer 267 
has not been exclusively demonstrated and it remains unclear if serum TSH concentrations are 268 
higher as a consequence of the presence of thyroid malignancy.  269 
A further potential explanation is that patients with lower serum TSH concentrations already 270 
have or are progressing towards development of autonomously functioning thyroid nodules, which 271 
are less likely to be malignant (Hegedus 2004; Hegedus et al. 2003; Mann, et al. 1988). Fiore et al 272 
demonstrated significant age-dependent development of thyroid autonomy (serum TSH<0.4 mIU/l) 273 
in patients with benign thyroid disease but this was less evident in those with papillary thyroid 274 
cancer and in patients with multinodular goitre. The frequency of thyroid autonomy was higher and 275 
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the risk of papillary thyroid cancer was lower than in those with solitary nodules, consistent with a 276 
protective effect of lower serum TSH concentrations on thyroid cancer development or progression 277 
(Boelaert 2009; Fiore et al. 2009). 278 
Serum TSH and papillary microcarcinoma 279 
Papillary microcarcinomas, defined as thyroid cancer <10mm in diameter, are increasing 280 
dramatically in frequency, and distinguishing those that proliferate and progress aggressively from 281 
small indolent tumours is difficult. The increased incidence is partly due to the finding of 282 
incidentalomas on routine imaging as well as on histopathological examination of thyroid specimens 283 
removed for reasons not associated with the suspicion of malignancy (Roti, et al. 2008). Current 284 
guidelines do not recommend completion thyroidectomy nor the administration of radioiodine 285 
routinely for these tumours. A more conservative approach for their management has been 286 
recommended, and for low risk patients, who have isolated and intrathryoidal tumours, without 287 
nodal metastases, lobectomy is sufficient (Haugen et al. 2015; Pacini, et al. 2012; Perros et al. 2014). 288 
In those with evidence of metastases, a positive family history, previous radiation to the head and 289 
neck or in subjects older than 45 years, total thyroidectomy and radioiodine ablation may be 290 
indicated (Mazzaferri 2007; Perros et al. 2014; Pitoia and Miyauchi 2015).  291 
Two main difficulties arise from these modern guidelines: (i) a subset of these tumours 292 
progress and metastasise (Page, et al. 2009; Roti, et al. 2006); (ii) patients, when presented with a 293 
cancer diagnosis, often prefer comprehensive therapy, which leaves them with the best prognosis 294 
and the lowest risk of recurrence, often despite the potential cost of any associated treatment 295 
morbidity.  While current tumour staging systems are unable to guide therapy in papillary 296 
microcarcinomas, the potential for use of TSH to assist in assessing prognosis is appealing.  297 
The association between raised serum TSH measurements and papillary thyroid 298 
microcarcinoma has been studied (Table 4), and some have suggested this as a means to estimate 299 
thyroid cancer risk in those with thyroid nodule of less than 1 cm in size (Moon, et al. 2012). 300 
However not all studies are consistent. Sohn, et al. (Sohn, et al. 2014) demonstrated the association 301 
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between higher TSH and risk of malignancy in tumours over 1cm, but not in papillary 302 
microcarcinomas. Similarly, an Italian study showed that TSH was not significantly different in 303 
thyroid papillary microcarinoma patients compared to their controls consisting of patients with 304 
negative histology (Negro, et al. 2013; Sohn et al. 2014). A meta-analysis of nine studies 305 
encompassing 6,523 subjects demonstrated that some smaller studies were biased due to 306 
heterogeneous controls, and overall confirmed a significant association between higher serum TSH 307 
and papillary microcarcinoma, supporting the hypothesis that TSH is involved in differentiated 308 
thyroid tumorigenesis. The authors stated that there is insufficient evidence to show that TSH is 309 
directly involved in thyroid carcinoma initiation but the data support the hypothesis that raised TSH 310 
is associated with risk of cancer and progression (Shi et al. 2016). At present, it is unclear how the 311 
increased detection of small indolent microcarcinomas influences the utility of using serum TSH in 312 
clinical decision algorithms. 313 
Whether TSH is an important factor in disease initiation or progression remains unclear. An 314 
argument against its involvement in tumour initiation is the lack of TSH receptor mutations 315 
interfering with signal transduction in thyroid carcinomas (Matsuo, et al. 1993). Furthermore, 316 
thyroid carcinomas can occur in patients with a range of serum TSH, including in those who take 317 
exogenous thyroid hormones and have suppressed serum TSH concentrations for treatment of other 318 
thyroid diseases (Satta, et al. 1993). 319 
On the contrary, a mouse-model with a knock-in of oncogenic BRAF generated by Franco et 320 
al. developed invasive thyroid carcinomas and concomitantly became profoundly hypothyroid as 321 
demonstrated by significantly raised TSH levels. Following knockout of the TSH receptor (to 322 
genetically replicate ablation of the TSH signalling pathway) there was a significant lag in the period 323 
before tumour formation, and the tumours that developed were much less aggressive (Franco, et al. 324 
2011). These findings contribute to the idea that TSH per se may not be oncogenic independently, 325 





Serum TSH and follicular thyroid cancer 329 
Follicular thyroid carcinomas provide a unique diagnostic challenge, in that they cannot be 330 
diagnosed by cytological evaluation alone. While there may be factors indicating neoplastic change 331 
in fine needle aspirates, follicular carcinoma is defined as a tumour that invades the capsule, a 332 
feature that cannot be identified on cytological evaluation rendering these cancers indistinguishable 333 
from thyroid adenomas using cytopathology. The standard treatment of choice is therefore 334 
diagnostic hemithyroidectomy, which requires no further surgery in adenomatous lesions, but is 335 
usually followed up by completion hemithyroidectomy, radioiodine ablation and suppression of TSH 336 
in the majority of invasive follicular carcinomas (McHenry and Phitayakorn 2011; Perros et al. 2014; 337 
Pitoia and Miyauchi 2015).  338 
Raised serum TSH levels have been demonstrated in patients with follicular carcinoma 339 
compared to those with benign follicular disease (Kunt, et al. 2015). While the TSH level is unlikely to 340 
be the single factor in follicular thyroid cancer development, some have advocated using its 341 
measurement in combination with other determinators of risk stratification, even to the point of 342 
defining treatment, i.e. whether to proceed with hemithyroidectomy or not (Kuru, et al. 2009). 343 
Despite the potential for the application of TSH measurements in the management of follicular 344 
thyroid carcinomas, there is a paucity of studies addressing this specifically (Zheng et al. 2016). 345 
TSH and non-differentiated thyroid cancer 346 
Due to the different pathophysiology of medullary thyroid cancer, TSH concentrations are 347 
not implicated in the likelihood of diagnosis, nor in the follow up monitoring of these tumours. 348 
Responsiveness of thyroid cancer to TSH depends on TSH receptor expression, and  de-differentiated 349 
cancers demonstrate significant reductions in expression of thyroid specific proteins including TSH 350 
receptors, thyroid peroxidase and thyroglobulin (Brabant, et al. 1991; Sheils and Sweeney 1999). 351 
Anaplastic thyroid cancers represent extreme forms of dedifferentiated tumours and these tumours 352 
are characteristically very difficult to treat due to the lack of expression of proteins involved in the 353 
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thyroid machinery. Expression of the sodium iodide symporter is often absent, thereby significantly 354 
reducing the functional effectiveness of radioiodine ablation and treatment. Current therapeutic 355 
approaches include the re-differentiation of these tumours with various agents to improve 356 
treatability (Dong, et al. 2013; Kang, et al. 2011; Schmutzler and Kohrle 2000). In view of the 357 
inherent lack of expression of normal TSH receptors in anaplastic thyroid cancers, serum TSH 358 
concentrations have not been studied in relation to the diagnosis or progression of these tumours. It 359 
seems unlikely that finding of altered TSH levels in this context, would aid the choice of available 360 
treatment options nor would it affect the very poor prognosis associated with these rare thyroid 361 
cancers.   362 
TSH in follow up of patients with thyroid malignancy  363 
Until recently, the long term management of differentiated thyroid cancers included the 364 
suppression of serum TSH concentrations with supraphysiological concentrations of levothyroxine 365 
for extended periods of time, regardless of the tumour-specific risk stratification. Current guidelines 366 
recommend against TSH suppression into low risk tumours which have not been treated with 367 
radioiodine or those who are stratified in the excellent response categories following dynamic risk 368 
stratification (Haugen et al. 2015; Perros et al. 2014; Pitoia and Miyauchi 2015). For those tumours 369 
that have not undergone further risk stratification at 1-year post-treatment, current practice is to 370 
suppress TSH levels with exogenous thyroid hormone to less than 0.1 mU/l for 5-10 years post-371 
treatment. At this point, depending on the clinical response, the TSH suppression can be relaxed 372 
(Perros et al. 2014).  Some studies have indicated that TSH suppression may inhibit the generation of 373 
new thyroid nodules, as well as the growth and tumourigenic potential in existing nodules (Papini et 374 
al. 1998), although current guidelines do not recommend of thyroid hormone suppressive therapy in 375 
patients with thyroid nodules (Haugen et al. 2015; Perros et al. 2014; Pitoia and Miyauchi 2015). 376 
TSH suppression in differentiated thyroid cancer follow-up 377 
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 Suppressive serum TSH to very low level reduces the rates of thyroid cancer recurrence and 378 
has been shown to improve differentiated thyroid cancer patient outcomes. TSH is a growth factor 379 
for thyroid nodules, and it is considered that suppression of TSH can prevent new nodule formation 380 
as well as inhibition of current nodules (Papini et al. 1998). In the context of differentiated thyroid 381 
carcinoma treatment, after resection of thyroid carcinoma and radioiodine treatment, TSH 382 
suppression therapy positively affects cancer outcomes including disease-specific survival 383 
(Mazzaferri and Jhiang 1994), and reduces recurrence (Pujol et al. 1996). Therefore it is widely 384 
recommended that patients have TSH suppression after successful treatment in the early post-385 
operative period (Haugen et al. 2015).  386 
Risks associated with TSH suppression 387 
Despite the widespread use of TSH suppression in patients who have been treated for 388 
differentiated thyroid cancer, this treatment approach is not completely without risk. Subclinical 389 
hyperthyroidism has been demonstrated to have significant deleterious health conseqeunces. This 390 
includes a spectrum of cardiovascular risks, including atrial fibrillation and coronary heart disease 391 
morbidity and mortality (Collet, et al. 2012). There is also a documented association with dementia, 392 
decreased cognitive function (Annerbo and Lokk 2013) and osteoporosis (Biondi, et al. 2015; 393 
Polovina, et al. 2015). 394 
Outcomes for high grade thyroid cancers have been improved with TSH suppression and 395 
some advocate the need for more aggressive suppression in higher stage disease (Jonklaas, et al. 396 
2006). In view of the aforementioned risk factors associated with this approach, current guidelines 397 
(Perros et al. 2014) now recommend the use of tools including the FRAX score to determine bone 398 
health and fracture risk (Kanis, et al. 2008) in patients who are on suppressive therapy with 399 
levothyroxine for 5 years or longer during thyroid cancer follow-up. Overall an individualised 400 
approach combining assessment of the patient’s response to treatment and risk of disease 401 
progression with an evaluation of the potential health risks associated with long term TSH 402 
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suppression is advised in establishing the required dose and length of course of levothyroxine 403 
therapy.  404 
Conclusion 405 
Patients presenting with a thyroid nodule or thyroid enlargement should have their serum 406 
TSH measured as part of the initial assessment. Following our paper in 2006 (Boelaert et al. 2006), a 407 
significant body of evidence has accumulated confirming the association between higher serum TSH 408 
concentrations and likelihood of thyroid cancer diagnosis. A recent meta-analysis demonstrated this 409 
relationship in thyroid tumours of all sizes, including papillary microcarcinomas in adult as well as in 410 
paediatric thyroid cancers (Zheng et al. 2016). Several studies and meta-analyses have also 411 
established a relationship between raised TSH levels and cancer progression, and increased 412 
concentrations were associated with advanced disease and lymph node metastasis (Fiore et al. 413 
2009; McLeod et al. 2012; Zheng et al. 2016).  414 
The diagnostic accuracy of serum TSH as a biochemical predictor of malignancy however has 415 
not yet been established and meta-analyses have failed to provide conclusive data to provide a 416 
single useful cut-off value to pass TSH as an independent and validated test (McLeod et al. 2012; 417 
Zheng et al. 2016) and measurement of this biochemical marker has not yet been incorporated into 418 
clinical decision algorithms. There have been suggestions that its measurement may be useful in 419 
combination with other tests including ultrasonography and fine needle aspiration cytology. At a 420 
time when thyroid nodules are increasingly being diagnosed, and whilst the differentiation between 421 
benign and malignant lesions remains difficult in a significant proportion of subjects, it is important 422 
to consider incorporating TSH levels into the stratification of patients’ thyroid cancer risk.  423 
Furthermore, treatment with TSH suppression in the follow-up of patients with thyroid 424 
cancer has been re-evaluated. There are significant long term health risks associated with TSH 425 
suppression and further refinement of the stratification approaches regarding the risk of disease 426 
progression or recurrence will help identify those patients in whom the risks of long-term 427 
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suppressive therapy outweigh the risks. Large prospective studies to evaluate this further will be of 428 
utmost importance. Whilst there is little doubt that serum TSH is raised in differentiated thyroid 429 
cancer, the full integration of this finding into clinical pathways relating to the diagnosis and 430 
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Figure Legend 686 
Figure illustrating TSH binding to its receptor in normal thyroid physiology. Potential roles of 687 
high serum TSH concentrations in the initiation and progression of thyroid carcinogenesis as 688 
well as putative links with thyroid autoimmunity in the context of contributing 689 


















Table 1: Clinical features suggestive of thyroid malignancy (Hegedus 2004; Popoveniuc and 706 








  715 
History Physical examination 
Family Hx of MEN, MTC, PTC Firm nodule 
History of head and neck irradiation as 
child or adolescent 
Nodule fixed to adjacent structures 
History of Hodgkin and non-Hodgkin 
lymphoma and irradiation 
Growth of nodules, especially during 
therapy to suppress TSH 
Age < 20 Abnormal cervical lymph nodes 
Age > 70 Vocal cord paralysis 
Male gender  
Symptoms of compression: hoarseness, 




Table 2: US features associated with thyroid malignancy. (Perros et al. 2014) 716 
Benign nodule Malignant nodule: 
Papillary/medullary 
Follicular lesion 
Spongiform/honeycomb Solid and hypoechoic Hyperechoic/ 
homogeneous/halo benign  
Purely cystic Irregular margin Hypoechogencity/loss of 
halo suspicious 
Egg shell calcification Intranodular vasularity  
Iso/hyper echoic 
(hypoechoic halo) 
Absence of halo  
Peripheral vascularity Taller than wide  
 Microcalcifications  
  717 
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Significant findings Serum TSH 
‘cut off’ 
value 





1,500 UK Serum TSH is an independent predictor of 
malignancy in thyroid nodules. Risk of 
thyroid cancer rises in parallel with serum 
TSH in the normal range. 
0.9 – 5.5 
mU/litre 
(Polyzos, et al. 
2008) 
J Cancer Res 
Clin Oncol 
565 Greece Higher rates of thyroid malignancy in 
patients with TSH in upper tertile of 
normal range. 
1.5 – 4 
mIU/l 
(Haymart et al. 
2008) 
JCEM 843 US Higher serum TSH is associated with 
advanced stage-differentiated thyroid 
cancer. 
1.4 – 4.9 
mIU/litre 
(Jonklaas et al. 
2008) 
Thyroid 50 US Higher TSH is associated with increased 
likelihood of diagnosis of thyroid cancer. 
Patients with thyroid cancer have lower 
serum total T3 concentrations. 
1.8 – 5.5 
mIU/L 




1361 US Risk of thyroid cancer increases with 
increased TSH independent of age. 
No cut off 
value  





10,178 Italy Higher TSH in patients with T3-T4 disease 
and in those with lymph node metastases. 
Autonomously functioning thyroid 
nodules are less likely to be malignant. 
1.6 – 3.4 
mU/ml 
(Gerschpacher, 
et al. 2010) 
Thyroid 87 Austria TSH may play a role in thyroid cancer 
progression rather than oncogenesis. 
 





386 Spain TSH levels are higher in patients with DTC. 
Increment in tumour size rises in parallel 
with incremental rise in TSH. 
No cut off 
value 
 






High TSH level within the normal range is 
an independent risk factor for DTC and 
can be used as a diagnostic adjunct. 
2.31 - 4.80  
mIU/l 






Serum TSH may not be useful for clinical 
risk assessment of small thyroid nodules. 
2.13 – 4.2 
mU/L 




622 Brazil Risk of carcinoma in nodular disease rises 
in parallel with serum TSH. 
above 1.64 
mU/L 
(Khan, et al. 
2016) 
Asian Pac J 
Cancer Prev 
73 Pakistan Higher pre-surgical TSH correlates with 
thyroid cancer. 
 




1870 China Raised TSH is related to cancer stage but 





Table 4: Table summarising studies investigating TSH and papillary microcarcinoma 723 






(Haymart et al. 
2008) 
JCEM 843 US Escalating cancer risk with higher TSH level 
in microcarcinomas. More research 
warranted. 






TSH measurement in the context of thyroid 
micronodule can exclude cancer 
(Shi, et al. 
2012) 
Endocr J 1870 China TSH does not correlate with 
microcarcinoma presence and therefore 
TSH can only be linked with progression of 
carcinoma 




205 Italy No difference in serum TSH between 
papillary microcarcinoma group compared 
to controls  






Serum TSH may not be useful for clinical 
risk assessment of small thyroid nodules 
(Jiao and Zhou 
2015) 
Zhonghua Yi 
Xue Za Zhi 
365 China TSH is probably associated with 
oncogenesis in papillary microcarcinoma 
(PTMC) although it may only be involved in 
growth of pre-existing PTMC  
 724 
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